Earlier this year, Ionis’ CEO Brett Monia said that Tryngolza (olezarsen) would become the company’s first fully owned blockbuster drug, with that forecast having just become ...

AbbVie's multi-billion-dollar Apogee bid could further cement the former's leading position in the immunology space as competition heats up.

Absci Corporation has secured $100m in an underwritten offering while reporting positive first-in-human (FIH) data for its lead candidate ABS-201, leaving the biopharma company po ...

Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.

The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.

Immunai and Boehringer Ingelheim have entered into a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases.

Former FDA employees discussed whether the agency’s commitment to openness risks creating a lack of clarity on official policies.

Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.

RQ Bio has closed a $115m Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.

Antares will lead all research and apply its drug discovery engine to a “limited” number of undisclosed oncology targets until Novartis decides to license the asset in questio ...

From data lakes to streamlined production, Kriya, Opus, and Epicrispr discuss how technology is improving their operations.

Boehringer Ingelheim has collaborated with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer.